Key Clinical Points Cervical-Cancer Screening with Human Papillomavirus and Cytologic
Cotesting Cervical cancer screening in the United States should not start until the age of 21 …

Rebecca B. Perkins, MD, MSc, 1 Richard S. Guido, MD, 2 Philip E. Castle, PhD, 3 David
Chelmow, MD, 4 Mark H. Einstein, MD, MS, 5 Francisco Garcia, MD, MPH, 6 Warner K. Huh …

ABSTRACT A group of 47 experts representing 23 professional societies, national and
international health organizations, and federal agencies met in Bethesda, MD, September …

Screening for cervical cancer with DNA ploidy assessment by automated quantitative image
cytometry has spread throughout China over the past decade and now an estimated 1 …

Objectives Given the recent debate challenging the contribution of cytology in cervical
screening, we evaluated results of liquid-based cytology (LBC) and human papillomavirus …

Objectives The next round of the American Society for Colposcopy and Cervical Pathology
(ASCCP)-sponsored cervical cancer screening and management guidelines will …

HPV testing is more sensitive than cytology for cervical screening. However, to incorporate
HPV tests into screening, risk‐stratification (“triage”) of HPV‐positive women is needed to …

Objective Most women referred for colposcopy are not diagnosed with cervical intraepithelial
neoplasia grade 2 or worse (CIN 2+) but, nonetheless, are typically asked to return much …

Objectives Cervical screening strives to prevent cervical cancer (CxCa), minimizing
morbidity and mortality. Most large US reports on cytology and human papillomavirus (HPV) …

Objectives There is growing interest in using human papillomavirus (HPV) genotyping as a
risk-based triage approach for women with atypical squamous cells-undetermined …